Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.170
-0.030 (-2.50%)
At close: Nov 19, 2025, 4:00 PM EST
1.178
+0.008 (0.64%)
After-hours: Nov 19, 2025, 7:58 PM EST
Humacyte Revenue
Humacyte had revenue of $753.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $1.57M.
Revenue (ttm)
$1.57M
Revenue Growth
n/a
P/S Ratio
106.62
Revenue / Employee
$7,141
Employees
220
Market Cap
219.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | 1.49M | -4.70M | -75.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HUMA News
- 6 days ago - Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) - GlobeNewsWire
- 7 days ago - Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 9 days ago - Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025 - GlobeNewsWire
- 13 days ago - Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025 - GlobeNewsWire
- 20 days ago - Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma - GlobeNewsWire
- 6 weeks ago - Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering - GlobeNewsWire
- 6 weeks ago - Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™ - GlobeNewsWire